{
  "id": "69bddc62a3cf7519c15732a7f2ad41d76b939836",
  "title": "These 4 charts show the scale of Novo Nordisk's woes",
  "summary_full": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
  "summary_public": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
  "url": "https://www.cnbc.com/2026/02/25/novo-nordisk-stock-nvo-lly-eli-lilly-ozempic-weight-loss-obesity.html",
  "published_at": "2026-02-25T15:19:46+00:00",
  "source": "International: Top News And Analysis",
  "language": "en",
  "countries_detected": [],
  "countries_scored": [],
  "sentiment_by_country": null,
  "sentiment_error": null,
  "llm_version": null,
  "llm_perspective": null,
  "llm_attempted_at": null,
  "processed_at": null
}